COVID-19 pushed many companies to adjust their trial supply management approaches to keep their clinical trials on track during the pandemic.
Pharmaceutical Technology recently spoke with Calyx’s Sylvain Berthelot about the impact COVID has had on clinical trials, how the industry is approaching randomization and trial supply management now, and what we can expect as we move toward a post-pandemic world.
You can read the full article at the link below:
Necessity Drives Just-in-Time Approaches to Clinical Trial Supply
